Concord Biotech Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Concord Biotech Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $6.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Concord Biotech Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $6.9M Trade | TransData Nexus

Concord Biotech Limited

Indian Pharmaceutical Exporter · Immunosuppressants Specialist · $6.9M Total Trade · DGFT Verified

Concord Biotech Limited is an Indian pharmaceutical exporter with a total trade value of $6.9M across 3 products in 1 therapeutic categories. Based on 173 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Mycophenolate ($6.0M), Cyclosporine ($700.0K), Sirolimus ($232.7K).

Concord Biotech Limited — Export Portfolio & Destination Treemap

Concord Biotech Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Concord Biotech Limited? — Company Overview & Market Position

Concord Biotech Limited, established in 2000, is a leading Indian biopharmaceutical company specializing in the research, development, and manufacturing of fermentation-based Active Pharmaceutical Ingredients (APIs) and finished formulations. Headquartered in Ahmedabad, Gujarat, India, the company has expanded its global footprint, serving over 70 countries with a diverse product portfolio.

The company operates with a vertically integrated business model, encompassing API production, formulation development, and contract research and manufacturing services. This integration enables Concord Biotech to maintain stringent quality control and meet the evolving demands of the global pharmaceutical market.

What Does Concord Biotech Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Mycophenolate$6.0M 2Cyclosporine$700.0K

Product Portfolio — Top 3 by Export Value

Concord Biotech Limited exports 3 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Mycophenolate	Immunosuppressants	$6.0M	119	1.8%	6
2	Cyclosporine	Immunosuppressants	$700.0K	14	5.8%	2
3	Sirolimus	Immunosuppressants	$232.7K	40	1.2%	9

Concord Biotech Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $6.9M. The top category is Immunosuppressants (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Concord Biotech Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Concord Biotech Limited operates three state-of-the-art manufacturing facilities near Ahmedabad, Gujarat, India, each designed to meet international quality standards.

The Dholka facility, established in 2000, spans 112,302 square meters and comprises 22 manufacturing blocks. It specializes in the production of fermentation and semi-synthetic APIs, with a fermentation capacity of 450m³. This facility has been inspected and approved by global regulatory agencies, including the USFDA, EU GMP, Japanese PMDA, and ANVISA of Brazil.

In 2021, Concord Biotech commissioned the Limbasi facility, covering 596,309 square meters with 19 manufacturing blocks, including six fermentation blocks and 13 downstream processing blocks. This facility boasts a fermentation capacity of 800m³ and is equipped to handle complex fermentation and downstream processing, catering to major regulated markets.

The Valthera facility focuses on the production of finished formulations, including oral solids, oral liquids, and suspensions. It is designed to meet global regulatory standards such as USFDA and EU GMP, targeting both domestic and international markets.

3Key Leadership

Concord Biotech Limited is led by a team of seasoned professionals committed to driving the company's growth and innovation.

Mr. Sudhir Vaid serves as the Chairman and Managing Director. With a background in microbiology and extensive experience in the pharmaceutical industry, he has been instrumental in transforming Concord Biotech into a global leader in fermentation-based biopharmaceuticals.

Mr. Ankur Vaid, the Joint Managing Director and Chief Executive Officer, holds a B.Tech in Chemical Engineering and an MBA. With over 18 years in the pharmaceutical industry, he has been pivotal in leading key initiatives in research, development, and market strategy, contributing significantly to the company's success.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Concord Biotech Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Concord Biotech Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan, through rigorous regulatory filings and approvals.

In the United States, the company's Dholka facility has undergone multiple inspections by the USFDA, resulting in successful approvals for the manufacturing of various APIs. This facility is also registered with the FDA, allowing Concord Biotech to market its products in the U.S. market.

In the European Union, the Dholka facility has been inspected and approved by the EU GMP, Government of Upper Bavaria, ensuring compliance with European manufacturing standards. This approval facilitates the export of Concord Biotech's products to EU member countries.

In Japan, the company has received Drug Master File (DMF) registrations for Tacrolimus Hydrate from the Pharmaceuticals and Medical Devices Agency (PMDA), enabling the marketing of its products in the Japanese market.

Concord Biotech's commitment to quality and compliance has also led to approvals in other regulated markets, including Australia and the United Kingdom, further solidifying its global footprint.

2Emerging Markets

Concord Biotech Limited has strategically expanded its presence in emerging markets across Africa, Latin America, and Southeast Asia, leveraging WHO prequalification to enhance market access.

Concord Biotech Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Concord Biotech Limited has a robust standing with the U.S. Food and Drug Administration (FDA), underscoring its commitment to quality and regulatory compliance.

The Dholka facility has been inspected multiple times by the USFDA, resulting in successful approvals for the manufacturing of various APIs. This facility is registered with the FDA, enabling Concord Biotech to market its products in the U.S. market.

The company's adherence to cGMP standards and its proactive approach to regulatory compliance have facilitated these approvals, allowing Concord Biotech to supply high-quality pharmaceutical products to the U.S. market.

2WHO & EU GMP

Concord Biotech Limited's commitment to quality is demonstrated through its compliance with WHO and EU GMP standards.

The Dholka facility has been inspected and approved by the EU GMP, Government of Upper Bavaria, ensuring compliance with European manufacturing standards. This approval facilitates the export of Concord Biotech's products to EU member countries.

Additionally, the Valthera formulation facility has received inspections from the WHO for GMP, further validating the company's adherence to international quality standards.

CDSCO & Indian Regulatory

Concord Biotech Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Concord Biotech Limited operates in a competitive landscape, with several key players in the biopharmaceutical industry offering similar products.

In the immunosuppressant segment, competitors include companies like Novartis and Roche, which have established market presence and extensive product portfolios. In oncology, firms such as Pfizer and Merck are prominent, offering a range of oncology therapeutics.

Concord Biotech's focus on fermentation-based APIs and high-quality formulations positions it as a specialized player in the market. The company's commitment to quality, regulatory compliance, and a diversified product portfolio enables it to maintain a competitive edge in the industry.

2Key Differentiators

Concord Biotech Limited distinguishes itself through several key differentiators:

Specialized Manufacturing Capabilities: The company's expertise in fermentation and semi-synthetic processes allows for the production of complex APIs and formulations, catering to niche therapeutic segments.

Regulatory Compliance: Concord Biotech's facilities are inspected and approved by multiple global regulatory agencies, including the USFDA, EU GMP, and WHO, ensuring adherence to international quality standards.

Frequently Asked Questions — Concord Biotech Limited

How many pharmaceutical products does Concord Biotech Limited export from India?

Concord Biotech Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Mycophenolate ($6.0M), Cyclosporine ($700.0K), Sirolimus ($232.7K). Total export value is $6.9M.

What is Concord Biotech Limited's total pharmaceutical export value?

Concord Biotech Limited's total pharmaceutical export value is $6.9M, based on 173 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Concord Biotech Limited cover?

Concord Biotech Limited exports across 1 therapeutic categories. The largest are Immunosuppressants (100.0%, 3 products).

Get Full Concord Biotech Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.